In this week’s edition of InnovationRx, we look at Jennifer Doudna’s $1 billion plan to bring Crispr gene editing to the real world, using “boring” AI in clinics and more.
Vertex Pharmaceuticals Incorporated faces slowing Trikafta/Kaftrio sales and a stock-price divergence with peers. Click for this VRTX earnings update.
The company could finally be ready to deliver on years of promise.
Stablecoins have completely changed the way people and companies move money in 2026. People like to call them the boring, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results